Investigation of the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema.

March 10, 2026 updated by: Doç.Dr.Ömer Şevgin, Uskudar University

Investigating the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema Developing After Breast Cancer Treatment: a Randomized Controlled Trial

This study aims to investigate the effect of progressive resistance exercise training on the clinical findings and functional outcomes of lymphedema in individuals who develop upper extremity lymphedema after breast cancer treatment (surgery, chemotherapy and/or radiotherapy).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study is designed as a randomized controlled trial. Volunteers participating in the study will consist of individuals who have developed lymphedema after breast cancer and who agree to participate in the study. Volunteer female participants will be divided into 2 groups of equal numbers. Participants in the control group will receive lymphedema treatment, while participants in the exercise group will perform progressive resistance upper extremity exercises at home, 2 days a week for 12 weeks. All exercises will be performed with compression bandages. All participants will be evaluated before and after treatment using a hand dynamometer, the Disabilities of the Arm, Shoulder and Hand Scale, and the Lymphedema Quality of Life Questionnaire-Arm.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey (Türkiye)
      • Adana, Turkey (Türkiye)
        • Recruiting
        • Re-Heal Physiotherapist Sude BOYVADAOĞLU Healthy Living Center
        • Contact:
          • Sevinj RAFILI
          • Phone Number: +905411127284

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion criteria:

  • Being between 18 and 60 years of age.
  • Being included in the study 3 months after undergoing surgery.
  • Being able to tolerate compression bandages or compression garments.

Exclusion criteria:

- Individuals who need to restart active cancer treatment during the study period. - Being within the first 3 months after surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: control group
They will receive classic lymphedema physiotherapy.
Other: control
Classic lymphedema physiotherapy will be applied.
Experimental: exercise group
In addition to classic lymphedema physiotherapy, a progressive resistance exercise training program will be implemented.
Other: control
Classic lymphedema physiotherapy will be applied.
Other: exercise
In addition to classic lymphedema physiotherapy, a progressive resistance exercise training program will be implemented.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
LYMphedema Quality of Life
Time Frame: 14 weeks
The Lymphedema Quality of Life Questionnaire, a validated disease-specific QoL tool, was also administered at baseline and at day 28. Overall QoL is scored on a single item by the patient on a scale of 1-10.
14 weeks
Disabilities of the Arm, Shoulder and Hand
Time Frame: 14 weeks
Validated outcome measure that asks an individual to self-report about the ability to perform certain upper limb activities. Questions are responded on a 5-point Likert scale.
14 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Uskudar University

Investigators

  • Study Chair: Sevinj RAFILI, Uskudar University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 6, 2026

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

August 30, 2026

Study Registration Dates

First Submitted

February 26, 2026

First Submitted That Met QC Criteria

February 26, 2026

First Posted (Actual)

March 4, 2026

Study Record Updates

Last Update Posted (Actual)

March 12, 2026

Last Update Submitted That Met QC Criteria

March 10, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Uskudar96

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on control

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe